Hims & Hers peptide rollout faces limited 2026 revenue boost, analysts say

Traders Union
All News
Financial News
Hims & Hers peptide revenue outlook

Highlights

Hims will launch peptides including NAD+, sermorelin, and glutathione by year-end, but analysts expect limited 2026 revenue impact due to current market saturation and pending FDA approvals.
The peptide market is estimated at $2.2 billion to $3.3 billion, but analysts remain cautious about the pace of adoption and revenue growth compared to GLP-1 drugs.
With a U.S. compounding pharmacy and a 2025-acquired manufacturing facility, Hims is strategically positioned, yet consensus expects peptide revenue to build gradually over a five to ten-year horizon.

Peptide launch plan and regulatory timing

As reported by Reuters, Hims is positioning peptides as a longer-term growth category rather than a major revenue driver for 2026, even as management outlines a launch schedule for products that are already legal to manufacture.

Chief Executive Andrew Dudum told investors on Monday that the company by year-end will offer peptides including NAD+, sermorelin and glutathione, which are marketed for metabolic support, weight loss and immune function. Analysts say that lineup is less likely to meaningfully move revenue because NAD+ is already widely available and demand may be stronger for peptides still under FDA review.

Peptides, made from short chains of amino acids, are drawing growing consumer interest despite lacking FDA approval in many uses. In July, an advisory panel supported allowing compounding of six peptides despite FDA staff concerns over limited evidence on safety and effectiveness, but the recommendation is nonbinding and final FDA rulemaking could take about a year, according to industry experts.

Hims has also started stability and validation testing for BPC-157, a peptide used for tissue repair that is among the compounds under FDA review for possible manufacturing by U.S. compounders. Dudum has said the company is waiting for full and final rulemaking before selling peptides that remain under agency review, although Olympia Pharmaceuticals CEO Mark Mikhael says regulators could permit interim production through enforcement discretion.

Long-term market opportunity draws cautious support

Wall Street remains careful about the timing of returns even as some investors see a sizable market opportunity. Analysts estimate the peptide market at $2.2 billion to $3.3 billion, and several companies selling these treatments say demand has risen since the FDA began its review in April.

Paul Cerro, chief investment officer at Cedar Grove Capital Management, says investors should not expect peptides to scale as quickly as GLP-1 weight-loss drugs, which helped raise Hims' profile. Morningstar analyst Keonhee Kim adds that the prevalence of grey-market or unauthorized peptide purchases makes it difficult to judge the value of Hims' planned NAD+ offering.

Still, some analysts say Hims is well positioned because it already owns a U.S. compounding pharmacy and acquired a facility in 2025 that can manufacture peptides. Raul Shah of DocShah Financial says that gives the company an advantage over rivals, while Kim says Hims can afford to wait because it already has a large subscriber base, customer loyalty and a strong brand.

Chief Financial Officer Yemi Okupe says expanding into new specialties remains one of the company's core growth levers. Shah expects Hims' peptide business to generate more than $1 billion in revenue over the next five to 10 years, but he says that growth is likely to build gradually rather than arrive in the current year.

Our earlier coverage of Cava’s results highlighted how GLP-1 weight-loss drugs are reshaping eating habits, with more adult customers choosing the chain’s lower-priced kids’ meals for smaller portions. We noted that the shift aligns with rising demand for protein-focused, customizable meals and reflects a broader move toward tighter portion control across fast-casual dining.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.